Clinical Trial: NRG GU002

NRG GU002

Status: Closed

NCT#03070886

Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or Without Adjuvant Docetaxel

GU002 is closed to accrual, effective September 6, 2022.

The Montana Cancer Consortium (MCC) is an independent nonprofit organization whose mission is to bring state-of-the-art cancer care to Montana, Idaho and Wyoming through National Cancer Institute (NCI) sponsored clinical research.

Navigation

About Us

Contact Us

Copyright © Montana Cancer Consortium | All rights reserved